These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37348652)

  • 1. Renal anemia: current treatments and emerging molecules.
    Heras-Benito M
    Rev Clin Esp (Barc); 2023; 223(7):433-439. PubMed ID: 37348652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unresolved aspects in the management of renal anemia, a Delphi consensus of the Anemia Group of the S.E.N.
    Portolés J; Martín-Malo A; Martín-Rodríguez L; Fernández-Fresnedo G; De Sequera P; Emilio Sánchez J; Ortiz-Arduan A; Cases A;
    Nefrologia (Engl Ed); 2023; 43(5):517-530. PubMed ID: 37993379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR
    Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology.
    Cases A; Egocheaga MI; Tranche S; Pallarés V; Ojeda R; Górriz JL; Portolés JM
    Nefrologia (Engl Ed); 2018; 38(1):8-12. PubMed ID: 29128260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New expectations in the treatment of anemia in chronic kidney disease.
    López-Gómez JM; Abad S; Vega A
    Nefrologia; 2016; 36(3):232-6. PubMed ID: 27137103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
    Del Vecchio L; Locatelli F
    Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
    Wyatt CM; Drüeke TB
    Kidney Int; 2016 Nov; 90(5):923-925. PubMed ID: 27742192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-Inducible Factor-Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?
    Locatelli F; Del Vecchio L
    J Am Soc Nephrol; 2022 Nov; 33(11):1966-1979. PubMed ID: 36041790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia in conventional hemodialysis: Finding the optimal treatment balance.
    Hasegawa T; Koiwa F; Akizawa T
    Semin Dial; 2018 Nov; 31(6):599-606. PubMed ID: 29909605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety review.
    Locatelli F; Paoletti E; Del Vecchio L
    Expert Opin Drug Saf; 2023; 22(12):1179-1191. PubMed ID: 38111209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON.
    Wish JB
    Am J Nephrol; 2022; 53(5):366-371. PubMed ID: 35462360
    [No Abstract]   [Full Text] [Related]  

  • 17. Anemia in chronic kidney disease.
    Atkinson MA; Warady BA
    Pediatr Nephrol; 2018 Feb; 33(2):227-238. PubMed ID: 28412770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Anemia Associated with Chronic Kidney Disease: Plea for Considering Physiological Erythropoiesis.
    Kuragano T
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.